Business
Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress
Biohaven Ltd. (NYSE: BHVN) announced today that it presented clinical safety and efficacy data for BHV-1510 at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress, taking place from December 10-12, 2025, in London, United Kingdom. The presentation highlights Biohaven's novel next-generation trophoblast cell surface antigen 2 (Trop2) directed antibody drug conjugate (ADC), BHV-1510, in combination with Regeneron's anti-PD-1 cemiplimab demonstrating efficacy and manageab
About this update from Biohaven Ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"In a pretreated population of participants with advanced/metastatic cancer and the majority with prior PD-(L)1 treatment, BHV-1510 2.5 mg/kg Q3W plus cemiplimab resulted in confirmed objective response rates 3/5 (60%) in NSCLC, 4/4 (100%) in endometrial cancer, and 1/2 (50%) in urothelial cancer","length":301,"tagName":"p"}]},{"val":[{"type":"text","content":"There were low rates of adverse events attributed to unconjugated payload such as hematological toxicities and diarrhea, and there were no cases of interstitial lung disease, showing a differentiated safety profile of BHV-1510 from other Trop2 ADCs","length":248,"tagName":"p"}]},{"val":[{"type":"text","content":"BHV-1510, a highly differentiated Trop2 ADC incorporating the proprietary TopoIx payload, demonstrates encouraging early clinical activity and favorable safety profile in a Phase 1 study in combination with the anti-PD-1 cemiplimab","length":236,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":785,"olType":false},{"type":"text","content":"LONDON and NEW HAVEN, Conn., Dec. 11, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) announced today that it presented clinical safety and efficacy data for BHV-1510 at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress, taking place from December 10-12, 2025, in London, United Kingdom. The presentation highlights Biohaven's novel next-generation trophoblast cell surface antigen 2 (Trop2) directed antibody drug conjugate (ADC), BHV-1510, in combination with Regeneron's anti-PD-1 cemiplimab demonstrating efficacy and manageable safety across several tumors.","length":604,"tagName":"p"},{"type":"image","alt":"Figure 1","displaySize":"","headline":null,"caption":"Figure 1","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":267,"url":"https://media.zenfs.com/en/prnewswire.com/c00ee0682be62105cb32531d64f595a8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TAgKgOYx1jXsLewLL_RoOg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ3MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/c00ee0682be62105cb32531d64f595a8","width":400,"height":267}},"href":"https://mma.prnewswire.com/media/2842225/BHVN_Figure_1___Target_Lesion_Change_from_Baseline.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"At the...